Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RCKTĀ – Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.
RCKT
$2.53
Name : Rocket Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $272,577,152.00
EPSttm : -2.63
finviz dynamic chart for RCKT
Rocket Pharmaceuticals, Inc.
$2.53
2.32%
$0.06

Float Short %

14.07

Margin Of Safety %

Put/Call OI Ratio

0.29

EPS Next Q Diff

0.05

EPS Last/This Y

0.61

EPS This/Next Y

0.63

Price

2.51

Target Price

9.03

Analyst Recom

2

Performance Q

-67.89

Relative Volume

1.17

Beta

0.68

Ticker: RCKT




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02RCKT2.780.390.2228370
2025-06-03RCKT2.960.390.0428795
2025-06-04RCKT2.920.380.5628999
2025-06-05RCKT2.780.380.0429229
2025-06-06RCKT3.070.380.0529357
2025-06-09RCKT3.030.370.3030086
2025-06-10RCKT3.160.370.1330079
2025-06-11RCKT3.040.360.0230291
2025-06-12RCKT3.060.350.3930628
2025-06-13RCKT2.930.340.0030382
2025-06-16RCKT2.870.341.2330379
2025-06-17RCKT2.710.330.2830259
2025-06-18RCKT2.820.320.3629916
2025-06-20RCKT2.690.320.3529982
2025-06-23RCKT2.640.260.8221413
2025-06-24RCKT2.770.260.0321754
2025-06-25RCKT2.650.261.2021810
2025-06-26RCKT2.590.273.2721972
2025-06-27RCKT2.520.290.1522302
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02RCKT2.7826.9- -2.13
2025-06-03RCKT2.9626.9- -2.13
2025-06-04RCKT2.9226.9- -2.13
2025-06-05RCKT2.7726.9- -2.13
2025-06-06RCKT3.0726.9- -2.12
2025-06-09RCKT3.0227.3- -2.12
2025-06-10RCKT3.1627.3- -2.12
2025-06-11RCKT3.0327.3- -2.12
2025-06-12RCKT3.0727.3- -2.12
2025-06-13RCKT2.9427.3- -2.12
2025-06-16RCKT2.8727.3- -2.12
2025-06-17RCKT2.7127.3- -2.12
2025-06-18RCKT2.8327.3- -2.12
2025-06-20RCKT2.7027.3301.6-2.12
2025-06-23RCKT2.6429.0- -2.12
2025-06-24RCKT2.7629.0- -2.12
2025-06-25RCKT2.6629.0546.4-2.12
2025-06-26RCKT2.5829.0- -2.12
2025-06-27RCKT2.5129.0- -2.12
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02RCKT-0.31-6.5313.98
2025-06-03RCKT-0.31-6.5313.98
2025-06-04RCKT-0.31-6.5313.98
2025-06-05RCKT-0.31-6.5313.98
2025-06-06RCKT-0.31-6.5313.98
2025-06-09RCKT-0.31-6.4913.98
2025-06-10RCKT-0.31-6.4913.98
2025-06-11RCKT-0.31-6.4912.67
2025-06-12RCKT-0.31-6.4912.67
2025-06-13RCKT-0.31-6.4912.67
2025-06-16RCKT-0.31-13.5012.67
2025-06-18RCKT-0.31-13.5012.67
2025-06-20RCKT-0.31-13.5012.67
2025-06-23RCKT-0.31-13.8012.67
2025-06-24RCKT-0.31-13.8012.67
2025-06-25RCKT-0.31-13.8012.67
2025-06-26RCKT-0.31-13.8014.07
2025-06-27RCKT-0.31-13.8014.07
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS​

-0.56

Avg. EPS Est. Current Quarter

-0.53

Avg. EPS Est. Next Quarter

-0.51

Insider Transactions

-0.31

Institutional Transactions

-13.8

Beta

0.68

Average Sales Estimate Current Quarter

4

Average Sales Estimate Next Quarter

Fair Value

Quality Score

13

Growth Score

25

Sentiment Score

10

Actual DrawDown %

96.3

Max Drawdown 5-Year %

-96.5

Target Price

9.03

P/E

Forward P/E

PEG

P/S

P/B

0.66

P/Free Cash Flow

EPS

-2.63

Average EPS Est. Cur. Y​

-2.12

EPS Next Y. (Est.)

-1.49

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

1.17

Return on Equity vs Sector %

-86.5

Return on Equity vs Industry %

-68.6

EPS 1 7Days Diff

EPS 1 30Days Diff

0.09

EBIT Estimation

Rocket Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 299
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
stock quote shares RCKTĀ – Rocket Pharmaceuticals, Inc. Stock Price stock today
news today RCKTĀ – Rocket Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RCKTĀ – Rocket Pharmaceuticals, Inc. yahoo finance google finance
stock history RCKTĀ – Rocket Pharmaceuticals, Inc. invest stock market
stock prices RCKT premarket after hours
ticker RCKT fair value insiders trading